drugset / Trial / NCT04066348

TNF-α Treatment of Blast-Induced Tinnitus

NCT04066348

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and/or noise exposure or associated with Traumatic Brain Injury (TBI) and/or concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.

Timeline

Start
2022-07-01
Primary completion
2026-09
Completion
2026-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Other

Indications